Latest Cytori Therapeutics Stories
- Alliance for Regenerative Medicine Announces Final Disease Session Panelists; 16 leading regenerative medicine companies discuss late stage and commercial products - WASHINGTON, April 9, 2013 /PRNewswire/ -- At the first annual Regen Med Investor Day, Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), Cytomedix, Inc. (OTCQX: CMXI) and Mesoblast Limited will be just three of the 16 leading regenerative medicine companies providing updates on recent corporate and clinical...
WASHINGTON, Jan. 3, 2013 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that 18 ARM members will be presenting at the Biotech Showcase 2013 meeting in San Francisco next week. Featuring company presentations by leading organizations in the industry, Biotech Showcase, produced by EBD Group and Demy-Colton Life Science Advisors, has emerged as a high profile...
WINNIPEG, Manitoba, Dec. 11, 2012 /PRNewswire/ -- Doug Broeska, Ph.D., CEO of Regenetek Research Inc., an international medical research company with offices in Canada and India has announced that they are launching new web-based, self-managing, clinical trial software that amongst other things will be able to extend patient Registry information into individual patient case studies and aggregate the data with comparisons to cohorts. The company has so far specifically focused their...
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're...
Cytori Therapeutics (NASDAQ: CYTX) has entered into a $15 million loan facility with GE Healthcare Financial Services and Silicon Valley Bank. An initial term loan of $7.5 million, minus fees and expenses, funded October 14, 2008. Cytori will be able to exercise the additional $7.5 million term loan on or before December 12, 2008, provided the Company meets certain financial prerequisites established by the lenders. GE Healthcare Financial Services' financing solution will be used to...
Cytori Therapeutics (NASDAQ:CYTX) reports financial results for the quarter ended June 30, 2008. During the second quarter, there was continued demand for Cytori's Celution(R) System in Europe and Asia among plastic and reconstructive surgeons. System sales in the first half of 2008 accomplished the Company's initial goal of installing devices at key surgical centers and with luminary surgeons. Cytori anticipates significant revenue growth for the remainder of 2008, resulting from...
Cytori Therapeutics (NASDAQ:CYTX) entered into a Binding Letter of Intent to complete a StemSource(R) Cell Bank sales agreement with Astrea International. Astrea has committed to purchase one StemSource Cell Bank for Singapore following receipt of regulatory clearance in Singapore on a pending application on the use of the Celution(R) System for tissue banking. In addition, Astrea has obtained rights from Cytori to commercialize additional StemSource Cell Banks in Malaysia and Brunei. "The...
Cytori Therapeutics (NASDAQ:CYTX) and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) formed collaboration to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The Fraunhofer Society will commit $425,000 over two years in support to Cytori's already planned research and development. The goal of the collaboration is to advance adipose-derived stem and regenerative cells into clinical trials for ischemic stroke. The underlying damage in...
Cytori Therapeutics (NASDAQ:CYTX) received its first orders from Europe and Asia for Celution® 800 Systems. The devices are now being sold into the growing international reconstructive surgery market. Eleven Celution™ 800 Systems and related CT-805 single-use consumables were ordered by Cytori's distributors MBA Grupo, who covers Spain, Italy, and Portugal, and Astrea International, who covers Singapore. The first devices are expected to be delivered in the first quarter of...
